CannabisNewsBreaks

FridayJan 13, 2023 11:34 am

CannabisNewsBreaks – IBN Expands Collaboration with NECANN for 2023 Event Series

IBN, a multifaceted financial news and publishing company, today announced expansion of its multi-year collaboration with NECANN to serve as an official newswire for its upcoming conferences in 2023. NECANN organizes events around the establishment and growth of cannabis markets and associated opportunities in carefully selected communities with the potential to usher in the normalization of consumption and supportive policy frameworks. Under the collaboration, IBN will provide additional outreach via its syndication network for NECANN events, leveraging an extensive array of corporate-communications solutions to heighten visibility and drive recognition of conference participants among various audiences. “NECANN events are unique for…

Continue Reading

ThursdayJan 12, 2023 2:32 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Moves Closer Toward Broad Applications of Patented DehydraTECH(TM)

Lexaria Bioscience Corp. (NASDAQ: LEXX) in 2022 achieved crucial milestones centered around its patented DehydraTECH(TM) drug delivery technology. “For Lexaria, the end goal does not only lie in uncovering DehydraTECH’s ability to improve the bioavailability of various APIs. Instead, the company is keen on establishing whether DehydraTECH can be applied broadly within the pharmaceutical industry. And calendar 2022 has brought Lexaria closer to realizing this goal, with the company initiating a slew of research programs, many of which it has already completed. Moreover, its intellectual property (‘IP’) portfolio received additional patent protection in different jurisdictions around the world. Lexaria also…

Continue Reading

TuesdayJan 10, 2023 11:38 am

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Key Milestones, 2023 Business Outlook

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today outlined key accomplishments from 2022 and provided a business update and catalysts for 2023. “Over the course of 2022, we strengthened our position as a leader in rare cannabinoid R&D, creating a unique offering as the only company that has the breadth and depth in cannabinoid drug research, development and significant manufacturing know-how,” said Eric A. Adams, InMed president and CEO. “Despite the many economic pressures affecting businesses on a global scale, including challenging capital markets, particularly in biotech, InMed…

Continue Reading

MondayJan 09, 2023 1:13 pm

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Leveraging Colombia, US Facilities to Distinguish Itself Within Highly Competitive Space

Flora Growth Corp. (NASDAQ: FLGC), a cannabis cultivator and global distributor, is a rapidly growing house of brands building customer bases and distribution channels across international lines as it aims to distinguish itself within a highly competitive arena. “Much of Flora Growth’s strength lies in its licensed cultivation, extraction and isolation facility located in northern Colombia’s fertile climate, where an experienced labor force is helping the nation emerge from decades of drug war illicit trade into a recognized and regulated market,” a recent article reads. “From its 247 acres of growing fields, the company’s harvests move into a production pipeline…

Continue Reading

ThursdayJan 05, 2023 11:24 am

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Releases Status Update on Commercial Cannabis Export Business

Flora Growth (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is reporting on its commercial cannabis operations out of Colombia. According to the status update, the company exported an estimated 1,000 kilograms of commercial cannabis dry flower and derivatives to Europe and the United States in the fourth quarter of 2022; the company also received an updated cannabis export and production quota from the Colombian government, which included the addition of four additional proprietary genetics and increased production for domestic medical markets. The company noted that this activity is a result of the full…

Continue Reading

WednesdayJan 04, 2023 10:53 am

CannabisNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Set to Begin IGC-AD1 Phase 2 Trials at Sites Throughout Canada

India Globalization Capital (NYSE American: IGC) today announced its receipt of a no objection letter from Health Canada for approval of its “Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial of the Safety and Efficacy of IGC-AD1 on Agitation in Participants with Dementia due to Alzheimer’s Disease.” The letter provides the acknowledgement of IGC-AD1’s drug candidacy and the authority to proceed with phase 2 trials in Canada. “We are pleased to have received this no objection letter from Health Canada, which allows us to begin phase 2 trials on our drug formulation IGC-AD1 at sites throughout Canada,” said Ram Mukunda, CEO…

Continue Reading

ThursdayDec 29, 2022 12:21 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures 28th Patent in International Portfolio

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its continued accumulation of international patent recognition with the receipt of its first granted patent in Canada, which is its 28th granted patent worldwide. According to the update, Canadian Patent #3,093,414 is the first granted patent from Lexaria’s sixth patent family and is entitled “Transdermal and/or Dermal Delivery of Lipophilic Active Agents.” The patent covers improved compositions and methods for dermal and transdermal delivery of cannabinoids, including cannabidiol (“CBD”) and tetrahydrocannabinol (“THC”). Similar patent applications for skin-based delivery of DehydraTECH(TM) formulations are pending in many other…

Continue Reading

TuesdayDec 27, 2022 1:47 pm

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Closes on Acquisition of Multinational Medical Cannabis Operator

Flora Growth (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, has completed a “plan of arrangement,” or acquisition, of Franchise Global Health Inc. (TSX.V: FGH), a multinational operator in the medical cannabis and pharmaceutical industry with principal operations in Germany. Shareholders of Global Health Inc. approved the plan, which was effective as of Dec. 23, 2022. FLGC anticipates that the acquisition will provide a direct connection between Flora Growth’s Colombian-grown cannabis and German-based pharmaceutical and medical cannabis distribution. The company also noted that the acquisition will establish a foothold in Germany for medical cannabis…

Continue Reading

WednesdayDec 21, 2022 2:44 pm

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-CBD (TM) Achieves Superior CBD Blood Absorption Levels in Hypertension Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that it has demonstrated superior cannabidiol (“CBD”) blood absorption levels from its patented DehydraTECH-CBD(TM) relative to those of published, pharmaceutical-grade CBD industry comparators. The results were obtained from the company’s recently completed, multi-week human clinical hypertension study – HYPER-H21-4. “DehydraTECH-CBD has repeatedly shown that it can be administered at much lower dose levels than other CBD formulations to achieve effective levels within the blood stream, as supported by this pharmaceutical-industry peer comparison,” said Chris Bunka, CEO of Lexaria Bioscience Corp. “This is extremely important to patients…

Continue Reading

TuesdayDec 20, 2022 3:28 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins Dosing in Its Human Oral Nicotine Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that dosing has begun in its human clinical nicotine study NIC-H22-1. Current cigarette smokers are participating in the 36-person human pharmacokinetic randomized, double blinded, cross-over study, wherein each person will visit the laboratory to be dosed three times over the coming weeks. Only one oral nicotine pouch (DehydraTECH-nicotine, On! brand manufactured by Altria, or Zyn brand manufactured by Swedish Match) will be administered and evaluated during each visit. The primary objectives are to determine the quantity of nicotine in blood at various time points and collection…

Continue Reading